Investing in Indian infrastructure companies: The recurring NBFC/CIC classification issue
This article explores the challenges of using multi-level corporate structures in India's infrastructure sector, more specifically due to the recurring and unintentional NBFC/CIC classification issue, and discusses exemptions for structures mandated by regulations, challenges for holding companies, and the potential way forward.
The Uniform Code for Pharmaceutical Marketing Practices 2024: A potential minefield for pharmaceutical companies
This article delves into the requirement for the introduction of the Uniform Code for Pharmaceutical Marketing Practices 2024, its enforceability, key differences from the previous version, compliances to be undertaken by pharmaceutical companies and medical device manufacturers, and certain aspects that remain unclear and are inconsistent.
